Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study
- PMID: 25851931
- DOI: 10.1007/s00535-015-1073-0
Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study
Abstract
Background: Proton pump inhibitor (PPI) therapy, the first-line treatment for gastroesophageal reflux disease (GERD), is not always effective. This study aimed to examine the effect of pretreatment patient characteristics on response to PPI therapy.
Methods: Japanese outpatients with symptomatic GERD scheduled to receive endoscopy and PPI therapy were enrolled in this multicenter prospective observational study. The patients' characteristics, including GERD and dyspeptic symptoms, anxiety, depression, and quality of life, were assessed using questionnaires before and 2 and 4 weeks after the start of PPI therapy. Factors affecting therapeutic response were examined by simple and multiple regression analyses using three patient-reported outcome measures as objective variables.
Results: Data from 182 patients were analyzed. In multiple regression analysis using the residual symptom rate as an objective variable, lower GERD symptom score (p < 0.05), absence of erosive esophagitis (p < 0.05), higher epigastric pain/burning symptom score (p < 0.05), and higher depression subscale score (p < 0.05) accompanied poorer therapeutic response. In analyses using the patient's impression of therapy, lower GERD symptom score (p < 0.05) and absence of erosive esophagitis (p < 0.05) accompanied poorer therapeutic response. In analyses using the relative GERD symptom intensity evaluated using a numeric rating scale, lower GERD symptom score (p < 0.05), higher epigastric pain/burning symptom score (p < 0.1), and lower body mass index (p < 0.05) accompanied poorer therapeutic response.
Conclusions: Patients who complained of milder GERD symptoms before treatment were likely to have poorer response to PPI therapy. Association of absence of erosive esophagitis, severer epigastric pain/burning symptoms, lower body mass index, and severer depression with poorer therapeutic response was also suggested.
Keywords: Anxiety; Depression; Dyspeptic symptoms; Gastroesophageal reflux disease; Therapeutic response to proton pump inhibitor therapy.
Similar articles
-
Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.J Gastroenterol. 2019 Jun;54(6):492-500. doi: 10.1007/s00535-019-01546-0. Epub 2019 Jan 23. J Gastroenterol. 2019. PMID: 30673836
-
Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.World J Gastroenterol. 2017 Mar 21;23(11):2060-2067. doi: 10.3748/wjg.v23.i11.2060. World J Gastroenterol. 2017. PMID: 28373773 Free PMC article.
-
Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?Intern Med. 2015;54(2):97-105. doi: 10.2169/internalmedicine.54.3412. Epub 2015 Jan 15. Intern Med. 2015. PMID: 25742999 Clinical Trial.
-
Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.Curr Gastroenterol Rep. 2017 Sep;19(9):46. doi: 10.1007/s11894-017-0586-5. Curr Gastroenterol Rep. 2017. PMID: 28780717 Review.
-
Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.World J Gastroenterol. 2014 Mar 7;20(9):2412-9. doi: 10.3748/wjg.v20.i9.2412. World J Gastroenterol. 2014. PMID: 24605040 Free PMC article. Review.
Cited by
-
Prevalence and risk factors of upper gastrointestinal symptoms in community pharmacies in Spain: a cross-sectional study.Front Pharmacol. 2023 Jun 13;14:1162370. doi: 10.3389/fphar.2023.1162370. eCollection 2023. Front Pharmacol. 2023. PMID: 37383720 Free PMC article.
-
Clinical features and therapeutic responses to proton pump inhibitor in patients with severe reflux esophagitis: A multicenter prospective observational study.JGH Open. 2020 Dec 8;5(1):99-106. doi: 10.1002/jgh3.12455. eCollection 2021 Jan. JGH Open. 2020. PMID: 33490619 Free PMC article.
-
Causal effect of anxiety and depression status on the symptoms of gastroesophageal reflux disease and functional dyspepsia during proton pump inhibitor therapy.Esophagus. 2023 Apr;20(2):309-316. doi: 10.1007/s10388-022-00960-3. Epub 2022 Oct 17. Esophagus. 2023. PMID: 36251168
-
Therapeutic strategy for the patients with coexisting gastroesophageal reflux disease and postprandial distress syndrome of functional dyspepsia.JGH Open. 2020 Feb 3;4(4):582-588. doi: 10.1002/jgh3.12299. eCollection 2020 Aug. JGH Open. 2020. PMID: 32782942 Free PMC article.
-
Clinical significance of gastroesophageal reflux disease with minimal change: a multicenter prospective observational study.Sci Rep. 2022 Sep 3;12(1):15036. doi: 10.1038/s41598-022-19408-w. Sci Rep. 2022. PMID: 36057730 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical